1-1 of 1
Andrew R. Carson
Close
Sort by
Journal Articles

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3 -ITD mutations

Clinical Trials & Observations
Mark J. Levis, Alexander E. Perl, Jessica K. Altman, Christopher D. Gocke, Erkut Bahceci, Jason Hill, Chaofeng Liu, Zhiyi Xie, Andrew R. Carson, Valerie McClain, Timothy T. Stenzel, Jeffrey E. Miller
Journal: Blood Advances
Blood Adv (2018) 2 (8): 825–831.
https://doi.org/10.1182/bloodadvances.2018015925
Published: 2018
Includes: Supplemental data